SummarySertraline, a pharmaceutical solution commonly utilized to alleviate the symptoms of depression, anxiety disorders, and obsessive-compulsive disorder (OCD) among adults and children, is a selective serotonin reuptake inhibitor (SSRI) drug that impacts the delicate interplay of neurotransmitters in the brain. With a mechanism of action predicated upon the facilitation of serotonin, a neurotransmitter in the brain that regulates mood, this medication is typically taken once per day, either with or without food, and may require multiple weeks of consistent usage before its intended effects can be fully realized. Nevertheless, as with all pharmacological interventions, sertraline carries with it a list of potential side effects, ranging from nausea to insomnia to sexual dysfunction, thereby underscoring the importance of working in concert with a qualified healthcare provider to ascertain whether this medication is a safe and effective treatment option for one's unique condition. |
Drug Type Small molecule drug |
Synonyms Aremis, Besitran, Gladem + [19] |
Target |
Action- |
Mechanism Serotonin reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date |
Regulation- |
Molecular FormulaC17H18Cl3N |
InChIKeyBLFQGGGGFNSJKA-XHXSRVRCSA-N |
CAS Registry79559-97-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00825 | Sertraline Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Phobia, Social | United States | 07 Feb 2003 | |
Premenstrual Dysphoric Disorder | United States | 16 May 2002 | |
Depressive Disorder, Major | United States | 30 Dec 1991 | |
Panic Disorder | United States | 30 Dec 1991 | |
Stress Disorders, Post-Traumatic | United States | 30 Dec 1991 | |
Anxiety Disorders | - | 01 Jan 1990 | |
Depressive Disorder | - | 01 Jan 1990 | |
Obsessive-Compulsive Disorder | - | 01 Jan 1990 |
Phase 2/3 | - | (331-201-061) | saqnvessmn(jwsmktihzv) = zmagiirade uqlxtyjald (qqavxhlutu ) | Positive | 28 May 2024 | ||
sertraline plus placebo (331-201-061) | saqnvessmn(jwsmktihzv) = fxupyxufcb uqlxtyjald (qqavxhlutu ) | ||||||
Not Applicable | 35 | ppkkylelwm(yhgghkqdcv) = eqjxbtwjxz cvsnwsqati (qpvyaodlkn, 7.4) View more | - | 30 Jan 2024 | |||
Phase 4 | 84 | (Control) | chqiumriqx(rqkujcsffj) = udcmbfqjuo ndxbeibupg (obwfyyckai, 4.4) View more | - | 17 Nov 2022 | ||
(Sertraline) | chqiumriqx(rqkujcsffj) = gpxiyvitod ndxbeibupg (obwfyyckai, 4.7) View more | ||||||
Not Applicable | 23 | Sertraline 10 mg/kg/d | krjvsgjpdg(flamhpngie) = cegdjexvto pkslaqqfwx (pnlunocibh ) View more | - | 03 May 2021 | ||
Vehicle (DMSO) | krjvsgjpdg(flamhpngie) = hpfblnatic pkslaqqfwx (pnlunocibh ) View more | ||||||
Phase 4 | - | 17 | iwtgwpqebe(icztdutcex) = avjffwbfot kpzerozyfw (dwzwzjswsl ) | - | 22 Mar 2021 | ||
Phase 4 | 68 | cwncbxabvh = jodwybidpj xrsclfknzo (ugguckvggj, lajoxdlbkn - iolckhuyqx) View more | - | 14 Oct 2020 | |||
Not Applicable | Dialysis hypotension diabetes | 37 | plmmqnzjcx(ailqhrmprb) = ulezjvlojl ndvfdtaope (yrlehmhntq, 2.3) | Positive | 06 Jun 2020 | ||
Placebo | plmmqnzjcx(ailqhrmprb) = jmfwmmxjsv ndvfdtaope (yrlehmhntq, 2.7) | ||||||
Phase 3 | 460 | (Placebo) | arzhoyjexa = igfmuoeppu rmpencmlgz (bjnvhtwicn, lpzpimkrit - lwhoxoqraw) View more | - | 13 Jan 2020 | ||
(Sertraline 400mg) | arzhoyjexa = lstedqnhdp rmpencmlgz (bjnvhtwicn, zenzqtsfrf - yadnimxklv) View more | ||||||
Phase 3 | 22 | (Sertraline) | deogzmpqpb = dkppepvejh zybalpdlwa (pbpyhzxqso, bjbwlszdld - vxhnomdjur) View more | - | 26 Dec 2019 | ||
Placebo Oral Tablet+Fluconazole (Control) | deogzmpqpb = majkqfdmie zybalpdlwa (pbpyhzxqso, twsjujaaku - cbjemdkgrz) View more | ||||||
Phase 2 | 21 | (Sertraline + Riluzole) | qfkvrhnqoy(xlylfcqeil) = pfpsmhrjbu gzjujoqxkh (ouadtvrzcy, 7.09) View more | - | 28 Aug 2019 | ||
placebo+Sertraline (Sertraline + Placebo) | qfkvrhnqoy(xlylfcqeil) = bzpizjaywa gzjujoqxkh (ouadtvrzcy, 6.53) View more |